Biosplice Therapeutics
PrivateLast Round
VC Round
Apr 15, 2021
Est. Valuation
$12.44B
Total Funding Raised
$878M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Biosplice Therapeutics is a biotechnology company that develops tissue-level therapeutic drugs for osteoarthritis, oncology, and other degenerative conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biosplice Therapeutics Comparables
Compare Biosplice Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OrthoTrophix, Inc. | 80% | |
| Kolon TissueGene, Inc. | 78% | |
| Eupraxia Pharmaceuticals Inc. | 77% |
Biosplice Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Apr 15, 2021 | ||||
| Series A Extension | Aug 6, 2018 | ||||
| Series A | Apr 13, 2016 |
Key People
Founding team and executive leadership
Biosplice Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SymBiosis Capital Management | VC Round |
| Polar Light Ventures | Series A Extension |
| Eventide Funds | VC Round |
| Ingka Investments | Series A |
| aMoon | VC Round |
| Starling Group | Series A Extension |
| Vickers Venture Partners | Early Funding, Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 48% MoM.
- Apr 15, 2021
$120M round with participation from Eventide Funds and Verition Fund Management.
Recent news
Latest coverage and updates
- is_developingSep 8, 2026
Biosplice Therapeutics, Inc. is developing LOR, a small-molecule drug that selectively inhibits DYRK1A and CLK2 for osteoarthritis, after more than a decade of development.
Biosplice Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessAppears On
Curated lists and screens where this company is featured.
Frequently Asked Questions
Common questions about Biosplice Therapeutics's valuation, stock price, and market status.
Is Biosplice Therapeutics a public or private company?
Biosplice Therapeutics is a private company.
What is the current stock price of Biosplice Therapeutics?
Biosplice Therapeutics is a private company, so its shares have no public market price. Caplight tracks Biosplice Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Biosplice Therapeutics worth (valuation)?
Biosplice Therapeutics's valuation is estimated at $12.4B based on funding round data.
Can I buy Biosplice Therapeutics stock?
Biosplice Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Biosplice Therapeutics's last funding round?
Biosplice Therapeutics's most recent funding round was VC Round on April 15, 2021.
Who are the main investors in Biosplice Therapeutics?
Key investors in Biosplice Therapeutics include Vickers Venture Partners.
Will Biosplice Therapeutics IPO soon?
No public IPO plans have been announced for Biosplice Therapeutics.
How can I track Biosplice Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Biosplice Therapeutics's shares on secondary markets.